Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy

J Infect Dis. 2021 Aug 16;224(4):673-678. doi: 10.1093/infdis/jiaa787.

Abstract

This multicountry prospective study investigated whether persistent systemic inflammation, measured by 8 plasma biomarkers, in HIV-1-infected Africans during suppressive antiretroviral therapy (ART) (viral load <50 copies/mL), was associated with CD4+ T-cell recovery and viral rebound (>1000 copies/mL) during long-term treatment. On-ART sCD14 and C-reactive protein concentrations were inversely associated with subsequent CD4+ T-cell counts. Risk of viral rebound was increased for participants with higher on-ART CXCL10 concentrations and reduced for those with a greater sCD163 decline during the first year of ART. Persistent systemic inflammation predicted CD4+ T-cell recovery and viral rebound, warranting further mechanistic research in relation to clinical outcomes.

Keywords: HIV-1; antiretroviral therapy; biomarkers; cytokines; immune activation; inflammation; sub-Saharan Africa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Biomarkers
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes* / immunology
  • HIV Infections* / drug therapy
  • HIV Seropositivity* / drug therapy
  • HIV-1
  • Humans
  • Inflammation / drug therapy
  • Prospective Studies
  • Viral Load

Substances

  • Anti-HIV Agents
  • Biomarkers